AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period.

ABSTRACT:

Background

Eliciting durable humoral immunity with sufficient breadth and magnitude is important for HIV-1 vaccine design. The HVTN 114 vaccine trial evaluated different boost regimens administered after a 7-year rest period in participants previously enrolled in HVTN 205, who received either three MVA/HIV62B (MMM) or two DNA and two MVA/HIV62B (DDMM) injections; both vaccines expressed multiple HIV-1 antigens in non-infectious virus-like-particles. The primary objective of HVTN 114 was to assess the impact of a heterologous gp120 protein AIDSVAX B/E boost on the magnitude, breadth and durability of vaccine-induced immune responses.

Methods

We enrolled 27 participants from HVTN 205 into five groups. Eight participants who previously received MMM were randomized and boosted w

SUBMITTER: Huang Y 

PROVIDER: S-EPMC8853668 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature